Home page Home page

Daronrix
pandemic influenza vaccine (whole virion, inactivated, adjuvanted)


PACKAGE LEAFLET: INFORMATION FOR THE USER


Daronrix, suspension for injection in pre-filled syringe

Pandemic influenza vaccine (whole virion, inactivated, adjuvanted)


Read all of this leaflet carefully before you start receiving this vaccine.


What Daronrix looks like and contents of the pack


Daronrix is a white, slightly milky liquid and is presented in a pre-filled syringe (0.5 ml) for 1 dose in pack sizes of 1 and 10 with or without needles


Not all pack sizes may be marketed.


Marketing Authorisation Holder


GlaxoSmithKline Biologicals s.a. Rue de l’Institut 89

B-1330 Rixensart Belgium


Manufacturer

Sächsisches Serumwerk Dresden (SSW) Zirkusstraße 40

D-01069 Dresden Germany


For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:


België/Belgique/Belgien GlaxoSmithKline s.a./n.v. Tél/Tel: + 32 2 656 21 11

Luxembourg/Luxemburg GlaxoSmithKline s.a./n.v. Tél/Tel: + 32 2 656 21 11


България ГлаксоСмитКлайн ЕООД Тел.: + 359 2 953 10 34

Magyarország GlaxoSmithKline Kft. Tel.: + 36-1-2255300


Česká republika GlaxoSmithKline s.r.o. Tel: + 420 2 22 00 11 11

gsk.czmail@gsk.com

Malta GlaxoSmithKline Malta Tel: + 356 21 238131


Danmark

GlaxoSmithKline Pharma A/S Tlf: + 45 36 35 91 00

info@glaxosmithkline.dk

Nederland GlaxoSmithKline BV Tel: + 31 (0)30 69 38 100

nlinfo@gsk.com


Deutschland

GlaxoSmithKline GmbH & Co. KG Tel: + 49 (0)89 360448701

produkt.info@gsk.com

Norge GlaxoSmithKline AS Tlf: + 47 22 70 20 00

firmapost@gsk.no


Eesti

GlaxoSmithKline Eesti OÜ Tel: +372 667 6900

estonia@gsk.com

Österreich

GlaxoSmithKline Pharma GmbH. Tel: + 43 1 970 75-0

at.info@gsk.com


Ελλάδα

GlaxoSmithKline A.E.B.E Tηλ: + 30 210 68 82 100

Polska

GSK Commercial Sp. z o.o. Tel.: + 48 (22) 576 9000


España GlaxoSmithKline, S.A. Tel: + 34 902 202 700

es-ci@gsk.com

Portugal

Smith Kline & French Portuguesa, Produtos Farmacêuticos, Lda.

Tel: + 351 21 412 95 00

FI.PT@gsk.com


France

Laboratoire GlaxoSmithKline Tél: + 33 (0) 1 39 17 84 44

diam@gsk.com

România

GlaxoSmithKline (GSK) SRL Tel: + 40 (0)21 3028 208

www.gsk.ro


Ireland

GlaxoSmithKline (Ireland) Ltd Tel: + 353 (0)1 4955000

Slovenija GlaxoSmithKline d.o.o. Tel: + 386 (0) 1 280 25 00

medical.x.si@gsk.com


Ísland GlaxoSmithKline ehf. Sími: +354-530 3700

Slovenská republika GlaxoSmithKline Slovakia s.r.o. Tel: + 421 (0)2 49 10 33 11

recepcia.sk@gsk.com


Italia

GlaxoSmithKline S.p.A. Tel:+ 39 04 59 21 81 11

Suomi/Finland GlaxoSmithKline Oy Puh/Tel: + 358 10 30 30 30

Finland.tuoteinfo@gsk.com


Κύπρος

GlaxoSmithKline Cyprus Ltd

Τηλ: + 357 22 89 95 01

Sverige GlaxoSmithKline AB Tel: + 46 (0)8 638 93 00

info.produkt@gsk.com


Latvija

GlaxoSmithKline Latvia SIA Tel: + 371 7312687

lv-epasts@gsk.com

United Kingdom GlaxoSmithKline UK Tel: + 44 (0)808 100 9997

customercontactuk@gsk.com


Lietuva

GlaxoSmithKline Lietuva UAB Tel. +370 5 264 90 00

info.lt@gsk.com


This leaflet was last approved in {MM/YYYY}.

Daronrix has been authorised under “Exceptional Circumstances”.

This means that for scientific reasons, it has not been possible to obtain complete information on this medicinal product.

The European Medicines Agency (EMEA) will review any new information on the medicine every year and this leaflet will be updated as necessary.


https://www.emea.europa.eu/